Furthermore, western blot results indicated that β-catenin, P-AKT,P-GSK-3β, Cyclin D1, Vimentin, and Bcl-2 protein expression in xenograft tumor were obviously reduced in SC66 treatment group (Figure 7D; Additional File 2: Figure S1J). The gene discussed is GSK3B; the disease is neoplasm.